Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Abstract: The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

Abstract: The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.

Abstract: The present application relates to securinine or norsecurinine analogs that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.

Abstract: The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

Abstract: A method for electronic gifting while simulating the wrapping and unwrapping experience in the real world is provided. The method comprises creation of a virtual package, by a giver, for temporarily concealing a virtual gift icon from a recipient using a concealing overlay. The concealing overlay may comprise one or more components, at least one of which forms a temporary barrier layer over the gift icon for temporarily concealing it. The gift icon is representative of any gifitable asset. The method also enables the recipient to interact with the virtual package for removing at least a portion of the concealing overlay from the virtual package for revealing the gift icon. A system implementing the method is also provided. The system comprises modules which enables the giver to create the virtual package and the recipient to interact with the virtual package.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Abstract: The present invention relates to novel securinine and norsecurine analogs that have reduced or non-reduced gamma-delta bond. The present invention also provides for methods of using securinine analogs, comprising administering one or more of the analogs to a myeloperoxidase enzyme, such as an enzyme with or proximal to a cell. As set out herein, the securinine analogs directly bind to and inhibit myeloperoxidase (MPO) activity. Accordingly, contacting or administering the analogs to an MPO enzyme allows for inhibition of MPO activity.

Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid disorders.

Abstract: A method for electronic gifting while simulating the wrapping and unwrapping experience in the real world is provided. The method comprises creation of a virtual package, by a giver, for temporarily concealing a virtual gift icon from a recipient using a concealing overlay. The concealing overlay may comprise one or more components, at least one of which forms a temporary barrier layer over the gift icon for temporarily concealing it. The gift icon is representative of any gifitable asset. The method also enables the recipient to interact with the virtual package for removing at least a portion of the concealing overlay from the virtual package for revealing the gift icon. A system implementing the method is also provided. The system comprises modules which enables the giver to create the virtual package and the recipient to interact with the virtual package.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Abstract: In general, a method includes determining metric values associated with data quality for one or more child nodes. Metric values are determined for a parent node based on the metric values of at least some of the child nodes, and relationships between one or more parent nodes and one or more child nodes define a hierarchy. The determination of the metric value for the parent node is repeated for multiple instances.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid disorders.